Inscrição na biblioteca: Guest
Ethics in Biology, Engineering and Medicine: An International Journal

ISSN Imprimir: 2151-805X

ISSN On-line: 2151-8068

SJR: 0.123

Ethics in Osteoporosis and Osteopenia: The Bare Bones of a Surrogate Marker

Volume 5, Edição 4, 2014, pp. 353-364
DOI: 10.1615/EthicsBiologyEngMed.2015013293
Get accessGet access

RESUMO

First you have a drug, and then you create the perception of need. The diagnosis of osteoporosis determined by bone density testing was promoted in 1995, simultaneously, and not coincidentally, with the FDA approval of the first major drug indicated for osteoporosis treatment. The use of bone density criteria greatly expanded the number of people who might be "diagnosed" to have osteoporosis or low bone density (commonly called "osteopenia") and therefore "eligible" for, or even requiring, medication to treat or prevent osteoporosis.
Osteoporosis is a true medical syndrome, but does this make low bone mineral density measurement (BMD) the equivalent? BMD is a surrogate for fracture risk, but it does not have as good a predictive value as other indicators, especially previous fracture or even advanced age. BMD improvement became a standard measure of drug efficacy in many clinical trials rather than the prevention of fracture, the true important outcome. Marketing to and by the medical community, as well as to prospective "patients", has created a huge medical market for a disease that followed the creation of new drugs.
Physicians are susceptible to influences from pharmaceutical companies and device manufacturers. While helpful in establishing understanding and awareness of osteoporosis as a common disease, this marketing served to identify additional patients for pharmacologic prevention and treatment of osteoporosis, with questionable results.

Última edição

Heroics at the End of Life in Pediatric Cardiac Intensive Care: The Role of the Intensivist in Supporting Ethical Decisions around Innovative Surgical Interventions Mithya Lewis-Newby, Emily Berkman, Douglas S. Diekema, Jonna D. Clark Transplantation for Older Patients with Hematologic Malignancies in 2021: Uncertainty and Ethics in Decision-Making H. Joachim Deeg Exploring the Hippocratic Oath: A Critical Look at Medicine's Oldest Surviving Guide to Medical Ethics D. John Doyle All Sore Eyes and Beasts: Spiritual Care Providers' Role in End-of-Life Existential Distress Debra Josephson Abrams, David B. Brecher, Douglas W. Lane The Ethics of Technology Development and Technology Use David W. Chambers Ethical Challenges of Artificial Intelligence in Health Care: A Narrative Review Aaron T. Hui, Shawn S. Ahn, Carolyn T. Lye, Jun Deng The Goods of Health Care Wade L. Robison The Ethics of Observing Low-Risk Thyroid Cancer Betty Y. Chen, Brendan C. Stack A Sampling of Engineering Ethics Conundrums Intended for Classroom Discussion D. John Doyle Toward a Better Understanding of Risk-Taking in Medical Decision Making David S. Dinhofer, Shweta Agarwal Ethical Issues Involving the Development of COVID-19 Vaccines: Role of Vaccine Development, Clinical Trials, and Speed of Peer Review in Dissuading Public Vaccine Hesitancy Leisha M. A. Martin, Gregory W. Buck Autonomy and Addictive Design Stephen Scales Ethical Implications with the Utilization of Artificial Intelligence in Dentistry Neekita Saudagar, Rafia Jabeen, Pallavi Sharma, Sean Mong, Ram M. Vaderhobli Meeting Report: 9th International Conference on Ethics in Biology, Engineering, and Medicine Subrata Saha, Pamela Saha Index, Volume 12, 2021
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa Políticas de preços e assinaturas Begell House Contato Language English 中文 Русский Português German French Spain